Cost-effectiveness of methods in personalized medicine. Results of a decision-analytic model in patients with acute myeloid leukemia with normal karyotype.

  title={Cost-effectiveness of methods in personalized medicine. Results of a decision-analytic model in patients with acute myeloid leukemia with normal karyotype.},
  author={Laura H{\"o}rster and Richard F. Schlenk and Michael E. Stadler and Maria M. Gabriel and Felicitas Thol and Jan Schildmann and Jochen Vollmann and Ursula Rochau and Gaby Sroczynski and J{\"u}rgen Wasem and Arnold Ganser and Matthias Port and Anja Neumann},
  journal={Leukemia research},

Healthcare expenses for treatment of acute myeloid leukemia

The authors provide an overview of the healthcare costs in patients with AML treated with various modalities and discusses whether these treatments are cost-effective from a societal perspective and how the increase in AML-associated costs can potentially be slowed.

Next-Generation DNA Sequencing-Based Gene Panel for Diagnosis and Genetic Risk Stratification in Onco-Hematology

The design, analytical validation and clinical feasibility evaluation of a molecular diagnostic kit based on sequencing of the coding regions of 76 genes, designed to detect large CNVs throughout the genome by including specific probes and employing a custom bioinformatics approach are included.


Being in the field of human genetic research and diagnostics since about 2 decades, during the last 10 years the author of this editorial was involved in numerous national and international education programs for young colleagues and observed, that some important aspects during education of future-CLGs definitely need more and special attention.

Cost-effectiveness of precision medicine: a scoping review

Key factors influencing cost-effectiveness included the prevalence of the genetic condition in the target population, costs of genetic testing and companion treatment and the probability of complications or mortality, and the willingness-to-pay thresholds varied widely.

1 Cost-effectiveness of precision medicine : a scoping review 2

Key factors influencing cost-effectiveness included the prevalence of the genetic condition in the target population, costs of genetic testing and companion treatment and the probability of complications or mortality.

Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review

The economic evidence for recent molecular biomarker tests in hematological malignancies and their availability in routine care largely depends on the supporting health economic evidence is reviewed.

Predicting of patient’s enrollment to multicentral international clinical trials of II–III phase

Recruitment of patient as an integrated part of site’s work could be calculated as the beginning of running study on particular site which can lead to increasing of study success and could be used as an embedded value in artificial intelligence for both virtual and real studies.

Nanotherapy and Reactive Oxygen Species (ROS) in Cancer: A Novel Perspective

Recent advances in the application of nanoparticles, alone or in combination with other drugs, as a promising anticancer tool are discussed, which could well minimize harmful side effects and improve patients’ health prognoses.

Calculation of Recruitment Which Were Proposed by Clinical Sites on Stage of Feasibility to Clinical Trial of II – III Phases

  • S. Milovanov
  • Medicine
    Corpus Journal of Clinical Trails (CJCT)
  • 2021
Recruitment of patients might be calculated which will decrease the number of failed clinical trials, and is proposed the formula for calculation of proposed recruitment of patients on the stage of feasibility.



Economic impact of genomic diagnostics for intermediate‐risk acute myeloid leukaemia

The results suggest that genomic analysis would result in a 26% increase in the use of first‐remission allogeneic stem cell transplantation, which would come at an additional cost of $12 556 per person and the incremental cost‐effectiveness ratio would be $49 493 per quality‐adjusted life‐year gained.

Personally Tailored Risk Prediction of AML Based on Comprehensive Genomic and Clinical Data

A novel prognostic framework based genomic sequencing data of 111 cancer genes matched with detailed diagnostic, treatment and survival data from 1,540 patients with AML enrolled in three different trials run by the German-Austrian AML Study Group is presented.

‘Acute myeloid leukemia: a comprehensive review and 2016 update'

The identification of recurrent genetic mutations, such as FLT3-ITD, NMP1 and CEBPA, has helped refine individual prognosis and guide management and here, the major recent advances in the treatment of AML are reviewed.

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.

Genetic predictors of outcome that improved risk stratification among patients with AML, independently of age, white-cell count, induction dose, and post-remission therapy, are identified and the significance of these predictors in an independent cohort is validated.

All-Trans Retinoic Acid Improves Outcome in Younger Adult Patients with Nucleophosmin-1 Mutated Acute Myeloid Leukemia – Results of the AMLSG 07-04 Randomized Treatment Trial

It is demonstrated that patients with mutated NPM1 and absence of a FLT3 internal tandem duplication (ITD) benefit from all- trans retinoic acid (ATRA) as adjunct to conventional chemotherapy in younger adult patients with AML.

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Genotypes defined by the mutational status of NPM1, FLT3, CEBPA, MLL, and MLL are associated with the outcome of treatment for patients with cytogenetically normal AML.

Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics.

These gene mutations have emerged as important prognostic markers and they now allow us to dissect cytogenetically normal (CN)-AML in distinct prognostic subgroups, and these mutant molecules represent potential targets for molecular therapies.

Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.

Compared with nonallogeneic SCT therapies, allogeneicSCT has significant RFS and overall survival benefit for intermediate- and poor-risk AML but not for good- risk AML in first complete remission.

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

An international expert panel is provided to provide updated evidence- and expert opinion-based recommendations for the diagnosis and management of AML, that contain both minimal requirements for general practice as well as standards for clinical trials.

Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation.

Multivariable analyses revealed a high allelic ratio as a predictive factor for the beneficial effect of allogeneic HSCT; ITD IS in TKD1 remained an unfavorable factor, whereas no prognostic impact of concurrent gene mutations was observed.